Evaluation of SARS-CoV-2 neutralization assays for antibody monitoring in natural infection and vaccine trials

Study Population & Specimen Collection

Residents of Blaine County, Idaho ≥18 years of age volunteered for study participation by completing a secure online intake form. Study volunteers were selected for participation using a two-phased approach. In the first phase, study volunteers were randomly selected for participation after stratification by ZIP code, and within ZIP code, age, gender and race/ethnicity. In the second phase, all volunteers who were Blaine County first responders and their families were selected for participation. Selected volunteers were invited for study participation in May 2020 and sent an electronic consent statement. Following enrollment, participants completed a questionnaire in REDCap, a secure software tool, to collect demographic information and symptom histories since January 15, 2020. Appointments for sample collection were scheduled upon survey completion. Blood was collected into 10 mL vials containing acid citrate dextrose and shipped overnight to the Fred Hutchinson Cancer Research Center. Plasma was separated by centrifugation at 1200×g for 15 mins and aliquoted into cryovials. One aliquot was submitted for Architect SARS-CoV-2 IgG assay (Abbott). Others were heat inactivated for 30 min at 56 °C, frozen at −80 °C and distributed to testing laboratories. Study participants were informed of the qualitative results of the Abbott IgG Serology assay via email within one week since obtaining test results. This study was approved by the Fred Hutch Institutional Review Board and all study materials were provided in both English and Spanish.

Protein antigens

A recombinant form of a synthetic construct (SARS_CoV_2_ectoCSPP (26); GenBank: QJE37812.1) of the spike (S) glycoprotein from SARS-CoV-2 Wuhan-Hu-1 was produced in human HEK293 cells (FreeStyle™ 293-F Cells, ThermoFisher, Waltham, MA) using a lentivirus expression system (27) and purified by nickel affinity and size-exclusion chromatography. Purity and solution monodispersivity were confirmed by comparative reduced/non-reduced PAGE, analytical size-exclusion chromatography, and static/dynamic light scattering on Uncle (Unchained Labs, Pleasanton, CA) and showed uniform trimerization. The recombinant protein was modified by replacing the native leader sequence with a murine Igk leader, removing the polybasic S1/S2 cleavage site (RRAR to A), stabilized with a pair of proline mutations (2P), and incorporating a thrombin cleavage site, a T4 foldon trimerization domain, a hexa-histidine purification tag, and a C-terminal Avi-Tag (28). After purification, the protein was sterile filtered and aliquoted in DPBS, no calcium, no magnesium (ThermoFisher). An analogous RBD-only version of this construct, swapping a TEV protease (29) site for the Thrombin site, was also produced following identical protocols. Alternatively, SARS-CoV-2 spike glycoprotein was produced as described elsewhere (23). Both spike protein preparations were tested in binding assay and no difference in recognition by serum and plasma samples from different convalescent subjects was found. SARS-CoV-2 nucleoprotein was purchased from GenScript (Piscataway, NJ) and tetanus toxoid from Lonza (Basel, Switzerland).

VSV-pseudovirus

The codon-optimized sequence of the SARS-CoV-2 spike protein (YP_009724390.1) with a truncation of the 19 C-terminal amino acids (D19) was cloned into a pcDNA3.1(+) vector (ThermoFisher) under control of the human CMV promoter to generate pcDNA3.1(+)-SARS-CoV-2-D19. The C-terminal truncation leads to a deletion of the ER-retention signal, localizing the spike protein to the cell surface, which enhances pseudovirus packaging (30). VSV(G*ΔG-luciferase) system was purchased from Kerafast (13, 31). Twenty-four hours prior infection with VSV(G*ΔG-luciferase), 293T cells were transfected with pcDNA-WuhanCoV-S-D19. Next day, supernatant was harvest, centrifuged for 5 min at 1,000xg, aliquoted and stored at −80 °C. TCID₅₀ was measured by infecting Vero cells (catalog number CCL-81; ATCC) with serial 2-fold dilutions of the prepared pseudovirus.

LV-pseudovirus

An expression plasmid encoding codon-optimized full-length spike of the Wuhan-1 strain (VRC7480), was provided by Drs. Barney Graham and Kizzmekia Corbett at the Vaccine Research Center, National Institutes of Health (USA). The D614G mutation was introduced into VRC7480 by site-directed mutagenesis using the QuikChange Lightning Site-Directed Mutagenesis Kit from (catalog number 210518; Agilent Technologies). The mutation was confirmed by full-length spike gene sequencing. Pseudovirions were produced in HEK 293T/17 cells (catalog number CRL-11268; ATCC) by transfection using Fugene 6 (catalog number E2692; Promega). Pseudovirions for 293T/ACE2 infection were produced by co-transfection with a lentiviral backbone (pCMV-ΔR8.2) and firefly luciferase reporter gene (pHR’-CMV-Luc) (32). Pseudovirions for TZM-bl/ACE2/TMPRSS2 infection were produced by co-transfection with the Env-deficient lentiviral backbone pSG3ΔEnv (kindly provided by Drs Beatrice Hahn and Feng Gao). Culture supernatants from transfections were clarified of cells by low-speed centrifugation and filtration (0.45 µm filter) and stored in 1 ml aliquots at −80°C.

Detection of IgG antibodies to SARS-CoV-2 using a commercial serologic assay

Plasma samples were tested at the Clinical Laboratory Improvement Amendments (CLIA)-certified University of Washington Virology lab using the Architect SARS-CoV-2 IgG assay (Abbott) under the Food and Drug Administration’s Emergency Use Authorization. The assay is a chemiluminescent microparticle immunoassay that measures IgG antibodies to the SARS-CoV-2 nucleocapsid protein. Qualitative results and index values reported by the instrument were used in analyses. Recommended index value cutoff of 1.40 was used for determining positivity (33).

Luminex SARS-CoV-2 IgG binding antibody assay

Protein antigens were coupled to the Bio-Plex Pro Magnetic COOH beads in a ratio of 10 μg of antigen per 2.5 x 10⁶ beads in a two-step carbodiimide reaction. First, beads were washed and resuspended in Activation Buffer (100 mM MES, pH 6) and then incubated with N-hydroxysulfosuccinimide (Sulfo-NHS, catalog number 24520; ThermoFisher) and 1-ethyl-3-[3-dimethlyaminopropyl]carbodiimide-HCl (EDC, catalog number 77149; ThermoFisher) also dissolved in Activation Buffer for 20 minutes on an end-over-end rotational mixer at room temperature protected from light. Activated beads were washed three times in Activation buffer. For coupling, antigen was mixed with activated beads and reaction was carried out for 2 h on a rotational mixer at room temperature protected from light. Conjugated beads were washed three times with Wash buffer (PBS, 0.05% Tween-20, 1% BSA, 0.1% NaN₃) and finally resuspended in Wash buffer at 10⁷ beads/ml. Beads were stored at 4 °C for no longer than 30 days.

Antigen-specific IgG was measured using two replicate dilutions. Beads were blocked with phosphate buffered saline (PBS; Gibco) containing 5% Blotto (Bio-Rad) and 0.05% Tween-20 (Sigma) and incubated for 1 hour with serially diluted plasma samples. Next, beads were washed 3 times with 0.05% Tween-20 in PBS and incubated with anti-human IgG Fc-PE (catalog number 2048-09; Sothern Biotech). After incubation with secondary antibody, beads were washed and resuspended in PBS with 1% BSA and 0.05% Tween-20 and binding data were collected on Bio-Plex 200 instrument (Bio-Rad). Median Fluorescence Intensity (MFI) was measured for a minimum of 50 beads per region. Background was established by measuring the MFI of beads conjugated to antigens but incubated in Assay buffer. Background MFI values were subtracted from all readings. We also trialed unconjugated beads and beads conjugated to a decoy antigen with the same plasma samples used in testing and did not detect non-specific binding above the assay background described above. Pooled sera from normal human donors collected in 2015 – 2016 was included as the negative control for SARS-CoV-2 antigens. For the positive control we used convalescent plasma from a subject with PCR-confirmed severe COVID-19.

An IgG standard curve run in duplicate was used to estimate IgG concentration. Anti-human IgG Fab-specific (Southern Biotech) was conjugated to the same bead regions used to conjugate to antigen proteins. IgG-coupled beads were blocked, washed and incubated with serially diluted human standard IgG (catalog number I4506; Sigma) for 1 h. Standard beads were washed and incubated with anti-human IgG Fc-PE and MFI was measured as described above. MFI readings and associated IgG concentrations were fitted to a four-parameter logistic curve (4PL) using the R packages nCal and drc. A standard curve for each experiment was used to obtain the effective concentrations of IgG in serum using the MFI measured with antigen-coated beads. Since serum samples were also run as a dilution series we used the median of the estimated concentrations from the dilutions that yielded MFIs between 100 and 10,000. Serum with all values above (below) this range were right (left) censored at the concentration of the minimum (maximum) MFI.

Live SARS-CoV-2 neutralization assay

Assay was carried out in BSL-3 suite. Vero E6 cells were seeded at 2×10⁴ cells/well in a 96-well plate 24 h before the assay. Seventy five pfu of the recombinant SARS-CoV-2-nanoLuc virus (rSARS-CoV-2-nLuc) (9) were mixed with Ab at 1:1 ratio and incubated at 37°C for 1h. A 8-points, 3-fold dilution curve was generated for each sample with starting concentration at 1:50. Virus and Ab mix was added to each well and incubated at 37°C + 5% CO₂ for 48h. Luciferase activities were measured by Nano-Glo Luciferase Assay System (Promega) following manufacturer protocol using SpectraMax M3 luminometer (Molecular Devices). Percent neutralization was calculated by the following equation: [1-(RLU with sample/ RLU with mock treatment)] x 100%.

VSV pseudovirus neutralization assay

Vero cells (ATCC® CCL-81™) were seeded at 2×10⁴ cells/well in a black-walled 96-well plates 24 hours before the assay. A 7-point, 3-fold dilution curve was generated with starting sample dilution at 1:20 in a separate round-bottom 96-well plate. 3.8×10² TCID50 of rVSV(G*ΔG-luciferase) pseudovirus with SARS-CoV-2-D19 spike protein (PsVSV-Luc-D19) was mixed with the plasma dilutions. Plasma-virus mixture was incubated at 37 °C in 5% CO₂ for 30 minutes. After incubation, plasma-virus mixture was transferred onto the Vero cells. Cells were then incubated at 37 °C, 5% CO₂ for 18-20 hours. Luciferase activity was measured by Bio-Glo Luciferase Assay System (catalog number G7940; Promega) following manufacturer protocol using 2030 VICTOR X3 multilabel reader (PerkinElmer). Percent virus neutralization was calculated by the following equation: [1-(luminescence of sample/ luminescence of cells+virus control)] x 100%. All the live virus experiments were performed under BSL-3 conditions at negative pressure, by operators in Tyvek suits wearing personal powered-air purifying respirators.

LV-pseudovirus neutralization assays

Neutralization of SARS-CoV-2 Spike-pseudotyped virus was performed by using lentiviral vectors and infection in either HEK 293T cells expressing human ACE2 (293T/ACE2.MF) or TZM-bl cells expressing both ACE2 and TMPRSS2 (TZM-bl/ACE2/TMPRSS2 cells). Both cell lines kindly provided by Drs. Mike Farzan and Huihui Mu at Scripps). Cells were maintained in DMEM containing 10% FBS, 1% Pen Strep and 3 ug/ml puromycin.

293T/ACE2 cells pseudovirus assay

For the 293T/ACE2 assay, a pre-titrated dose of virus was incubated with serial 3-fold dilutions of test sample in duplicate in a total volume of 150 ul for 1 hr at 37°C in 96-well flat-bottom black/white culture plates. Freshly trypsinized cells (10,000 cells in 100 ul of growth medium) was added to each well. One set of control wells received cells + virus (virus control) and another set received cells only (background control). After 68-72 hours of incubation, 100 ul of cell lysate was transferred to a 96-well black/white plate (catalog number 6005060; Perkin-Elmer) for measurements of luminescence using the Promega Luciferase Assay System (catalog number E1501; Promega). Neutralization titers are the serum dilution at which RLUs were reduced by 50% and 80% compared to virus control wells after subtraction of background RLUs. MPI is the reduction in RLU at the lowest serum dilution tested.

ACE2/TMPRSS2 TZM-bl cells pseudovirus assay

For the TZM-bl/ACE2/TMPRSS2 assay, a pre-titrated dose of virus was incubated with serial 3-fold dilutions of test sample in duplicate in a total volume of 150 ul for 1 hr at 37°C in 96-well flat-bottom culture plates. Freshly trypsinized cells (10,000 cells in 100 ul of growth medium containing 75 ug/ml DEAE dextran) were added to each well. One set of control wells received cells + virus (virus control) and another set received cells only (background control). After 68-72 hours of incubation, 100 ul of cell lysate was transferred to a 96-well black solid plate (Costar) for measurements of luminescence using the BriteLite Luminescence Reporter Gene Assay System (PerkinElmer Life Sciences). Neutralization titers are the serum dilution at which relative luminescence units (RLU) were reduced by 50% and 80% compared to virus control wells after subtraction of background RLUs. Maximum percent inhibition (MPI) is the reduction in RLU at the lowest serum dilution tested.

SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT)

Assay was performed according to manufacturer (GenScript) protocol and recommendations as follows. Capture plate was incubated with plasma samples diluted 1:10, washed and probed with secondary antibody. Assay was developed via TMB (ThermoFisher) and OD at 450 nm was measured using SpectraMax M2 reader (Molecular Devices). Positive and negative controls were provided in the kit. Binding inhibition was determined via the following formula: Inhibition = (1 – (OD of sample / OD of Negative control)) × 100%. Percent binding inhibition was interpreted as a percent neutralization. In order to determine ND50, plasma samples were serially diluted starting from 1:10 and assay was performed as described above.

Statistical Analysis and Visualization

Neutralization titers were defined as the plasma dilution that reduced relative luminescence units (RLU) by 50% or 80% relative to virus control wells (cells + virus only) after subtraction of background RLU in cells-only control wells. Fifty and 80 percent neutralization titers (ND50 and ND80) were estimated using the nCal and drc packages in R. RLU was first transformed to neutralization using the formula neut = 1 – ([RLU_sample – bkgd] / [RLU_VO – bkgd]). The neutralization vs. dilution curve was then fit with a 4PL model that was used to estimate the dilution at which there would be 50% or 80% neutralization. For samples with all dilutions having <50% neutralization the result was right censored at the highest concentration. Patient demographic information (sex and age) was extracted from a RedCap survey database. Abbott assay results (including index value) were extracted from the laboratory information system (Sunquest Laboratory).

Correlations were estimated between pairs of neutralization or binding antibody readouts using Pearson’s correlation coefficient (r); measures in units of neutralization and IgG concentration were logged prior to estimating correlation. Log-transformed ND50 values and IgG concentrations were approximately normally distributed with few outliers and a low level of censoring, justifying use of Pearson’s correlation and linear regression. Left censored values were given a value of half the level of detection, which corresponded to the first dilution for each neutralization assay. Student’s t test was also on log-transformed values. Association of neutralization and IgG concentration with age and BMI were conducted using Spearman’s rank-based correlation and Wilcoxon’s rank-sum tests were used to compare neutralization and IgG in two groups of individuals (e.g. gender, presence of symptom score >2). Statistical significance was determined based on a p-value < 0.05.

Cohort characteristics, demographics, survey participation, and serology clinical testing

A total of 1,359 email invitations were sent to 2,655 phase 1 study volunteers and 63 phase 2 volunteers. Among phase 1 and 2 volunteers invited to participate, 973 (72%) and 53 (84%) people consented and completed the enrollment survey. Of these, 967 participants presented for specimen collection between May 4-19, 2020, and 222 (22.8 %) with blood drawn had IgG antibodies to SARS-CoV-2 nucleoprotein according to the Abbott Architect test (index value ≥1.40).Out of these, we randomly selected forty positive samples to evaluate different platforms of SARS-CoV-2 neutralizing antibody assays. Participants had a median age of 51.5 years and a range between 23 and 81 years (Table 1). According to the survey, only one participant reported being hospitalized and four participants (10%) were self-described as asymptomatic. Among participants reporting different symptoms (Table S1), 57.5% had fever while fatigue (87.5%), cough (72.5%), headache (67.5%) and chills (65%) were more prevalent. Based on this, our cohort can be described as representing mild-to-moderate symptomatic infections.

Cell-based assays provided comparable estimates of neutralization activity

We tested forty heat-inactivated plasma samples in four different cell-based neutralization assays each with a different pair of target cells and virus (Table 2): live recombinant SARS-CoV-2 (rSARS-CoV-2-nLuc) with Vero E6 cells, a lentivirus pseudotyped by SARS-CoV-2 spike (LV-pseudovirus) with HEK 293T cells expressing human ACE2 (293T/ACE2) or TZM-bl cells expressing both ACE2 and TMPRSS2 (TZM-bl/ACE2/TMPRSS2) and a vesicular stomatitis virus (VSV) pseudotyped by SARS-CoV-2 spike (PsVSV-Luc-D19) with Vero cells; a fifth binding neutralization assay using competitive ELISA to assess inhibition of binding of hACE2 and SARS-CoV-2 RBD.

Fifty percent neutralizing dilution (ND50) is a standard numerical parameter to compare virus-neutralizing potency between different samples and studies. To reflect the ultimate capacity of serum antibodies to neutralize virus both ND50 and ND80, the dilutions at which 50% and 80% neutralization is observed, are used together. We serially diluted plasma samples to generate titration curves and estimated ND50 and ND80 relative to positive and negative controls (Fig. S1–S3). All four cell-based neutralization assays performed comparably and generated titration curves necessary for ND50 and ND80 estimation using a four-parameter logistic model (Fig. S1–S3). On average, the slope parameter for neutralization curves with rSARS-CoV-2-nLuc was higher compared to other assays (slope B=3.3 vs. 0.6, 1.4, 1.5 for LV-pseudo/293T, LV-pseudo/TZM-bl and VSV-pseudo/Vero, respectively; all p < 0.001). Geometric mean ND50 from the assay with rSARS-CoV-2-nLuc (141, 95% CI 94-213) did not differ (p=0.2) from the LV-pseudo/293T assay (178, 95%CI 112-283; Fig. 1A, Fig. S4A). However, the LV-pseudo/TZM-bl assay showed significantly lower geometric mean ND50s compared to LV-pseudo/293T (Fig. 1A, Fig. S4A). The VSV-pseudo/Vero assay produced significantly higher ND50 values (geometric mean ND50 of 310, 95%CI 211-454) compared to both the SARS-CoV-2/VeroE6 assay and the two LV-pseudovirus assays (Fig. S4A) suggesting that it is easier to neutralize VSV-based pseudovirus in Vero cells compared to other approaches.

• Download figure
• Open in new tab

Figure 1.

Boxplots of SARS-CoV-2 neutralization and binding antibody concentration for 40 plasma samples from 40 COVID-19 convalescent patients. (A) ND50 and (B) ND80 neutralization titer measured using five SARS-CoV-2 neutralization assays. Each assay defined its own lower limit of detect (LOD) based on the initial dilution: 50-fold for SARS-CoV-2/VeroE6, 20 for the LV and VSV pseudovirus assays and 10 for the sVNT. Data below the LOD (open triangle) is plotted at LOD/2. Number and percent of samples above the LOD is indicated above each plot. (C) Antigen-specific IgG concentration measured using a Luminex bead-based assay. (D) Index values for each sample from the Abbott Architect nucleoprotein IgG assay. For each assay the box represents the extend of the inter-quartile range (IQR) with a line indicating the median; whiskers extend to 1.5 times the IQR.

The assay platforms also differed in their capacity to detect neutralization. In the live-virus assay, LV-pseudo/293T and LV-pseudo/TZM-bl neutralization was detectable at the lowest dilution for 31, 37, and 34 samples, respectively, and therefore permitted estimation of the ND50; ND50 of the remaining samples was censored at the lowest dilution (Fig. 1A). In contrast, VSV-pseudo/Vero permitted estimation of ND50 for all 40 samples (Fig. 1A). With the sVNT, only 31 of 40 samples showed neutralization above 20%, a negative cutoff value according to the manufacturer’s protocol, at the lowest dilution 1:10 (Fig. S3A). To estimate ND50, we selected 13 of these 31 samples and tested them in serial dilutions (Fig. 1A, Fig. S3B). Samples were selected to represent different percent neutralization observed at 1:10 dilution. The resulting ND50 was significantly lower (29.5 95%CI 18.2-47.9) than in the cell-based assays, further supporting the conclusion that the surrogate assay had lower sensitivity compared to the cell-based assays.

We used the same 4PL models to estimate ND80 titers. Though ND80 was consistently lower, the correlation with ND50 was high ranging from Pearson’s r=0.87 for the live-virus assay to r=0.97 for the VSV-pseudovirus assay. Similar to ND50, the ND80 titers also differed among the assays (Fig. 1B, Fig. S4B) with the SARS-CoV-2/VeroE6 assay reporting the lowest number of samples with ND80 titers above the limit of detection (24/40) and VSV-pseudovirus assay showing the highest (39/40). The live-virus assay also showed the smallest difference between ND50 and ND80 titers (Fig. S5, Table S2), a direct consequence of the steeper titration curves observed for this assay (Fig. S1A). For pseudovirus-utilizing assays the difference between ND50 and ND80 was greater and ranged between 2.7 and 4.2-fold. Due to inability to reach 80% neutralization for the many samples in sVNT, we could not calculate ND80 (Fig. S3).

Strong correlation among neutralization assays

Next, we conducted a correlation analysis of the ND50 and ND80 values derived from each of the five neutralization assays (Fig. 2, Fig. S6). The live-virus and all three pseudovirus neutralization assays generated ND50 values that were highly correlated across samples (Pearson r = 0.81 – 0.89) with the highest correlation observed between the two LV-pseudovirus assays (Pearson r = 0.89, 95% CI [0.81, 0.94], p<0.001). ND50 reported by the sVNT showed the lowest correlation with the ND50 values from the cell-based assays (Pearson r = 0.41 – 0.60). In contrast, correlation was greater between the percent neutralization measured at 1:10 dilution and the outcomes of the cell-based assays (Pearson r = 0.73 – 0.80); correlation between ND50 and percent neutralization at 1:10 dilution was modest (r = 0.59).

• Download figure
• Open in new tab

Figure 2.

Correlation among assay readouts measuring neutralization or antigen-specific IgG concentration in plasma. Heatmap color is determined by the Pearson’s correlation coefficient (r, annotations). Each panel includes either ND50 titers (A) or ND80 titers (B) and their correlation with sVNT % neutralization, SARS-CoV-2 specific IgG concentration (Luminex bead-based assay), the quantitative index of the Abbott nucleoprotein assay and tetanus toxoid-specific IgG concentration.

Similar correlation was observed for ND80 outcomes for cell-based assays (Fig. 2B) with Person’s r ranging between 0.69 – 0.88. Only a few samples showed neutralization greater than 80% in sVNT (Fig. S3) and thus correlation between sVNT ND80 and other assays was not estimated.

Plasma concentration of IgG binding antibodies correlated with neutralization potency

Prior studies of SARS-CoV-2 individuals showed that the serum titer of spike and RBD-binding IgG antibodies was a correlate of neutralizing potency (14, 34, 35). Using quantitative, Luminex-based immunoassay, we measured concentration of IgG to SARS-CoV-2 spike, RBD and nucleoprotein in each of the serum samples; IgG to tetanus toxoid was also measured as a proxy for overall IgG level and state of humoral immunity (Fig. 1C). The mean concentration of nucleoprotein-specific IgG measured in the Luminex assay was 7.3 µg/ml (95%CI [5.3, 10]) while the concentration of both spike and RBD IgG was lower at 2.8 (95%CI [1.9 – 4.1]) and 2.1 µg/ml (95%CI [1.4, 3.3]), respectively. Concentration of tetanus-specific IgG was higher than IgG to SARS-CoV-2 antigens for all individuals (mean 14.5, 95%CI [11.1, 18.9]). Although Abbott SARS-CoV-2 IgG assay is designed and used for qualitative detection of IgG against the SARS-CoV-2 nucleoprotein, the instrument reports index values that can be used in quantitative analyses (Fig. 1D).

Pearson correlation analysis revealed that levels of RBD and spike IgG correlated strongly (Pearson’s r = 0.89, 95% CI [0.81, 0.94]) (Fig. 2A). Nucleoprotein-specific IgG measured in our Luminex immunoassay was highly correlated with the quantitative index of the Abbott Architect nucleoprotein IgG assay (Pearson’s r = 0.95, 95% CI [0.91, 0.97]). Correlation between levels of nucleoprotein IgG measured either in Luminex or Abbott assay moderately correlated with concentration of spike and RBD-specific IgG with Abbott indexes showing higher r values (Pearson’s r ranging 0.58 –0.68). There was no significant correlation of tetanus-specific IgG with SARS-CoV-2 spike, spike RBD or nucleoprotein IgG (all p > 0.05).

We then examined the relationship between concentration of SARS-CoV-2 IgG and virus neutralization (Fig. 2, Fig. S7). We found that IgG concentrations to each of the SARS-CoV-2 antigen was positively correlated with neutralization potency measured with each of the neutralization assays (Pearson’s r = 0.46 – 0.83; Fig. 2A). The correlation of live-virus neutralization ND50 with concentration of spike (Pearson r = 0.83, 95% CI [0.7, 0.91]) and RBD-specific (0.83 95% CI [0.7, 0.91]) IgG was comparable to the correlations observed with the other neutralization assays. Nucleoprotein-specific IgG concentration as well as the quantitative index from the Abbott test were only moderately correlated with ND50 obtained in cell-based assays, with r ranging between 0.46 – 0.63. In contrast the correlation of nucleoprotein-specific IgG was higher with the percent neutralization measured with the sVNT (Luminex, Pearson’s r = 0.69, 95% CI [0.49, 0.83] and Abbott, r = 0.76, 95% CI [0.54, 0.85]). Tetanus-specific IgG did not correlate with any of SARS-CoV-2-associated IgG concentrations or neutralization titers.

Effect of age, gender and disease symptoms

We explored if demographic and physiologic parameters were associated with SARS-CoV-2 specific IgG or neutralization. Previously, body mass index (BMI), female sex and age were reported to positively correlate with antibody titers against SARS-CoV-2 (36). We asked whether ND50 titers obtained from each neutralization assay correlated with age, gender, BMI or self-reported disease symptoms (Table 3). We found a moderate positive correlation between age and concentrations of spike-specific (Spearman’s rho=0.37, p=0.02), spike RBD-specific (rho=0.39, p=0.013) and nucleoprotein-specific (rho=0.45, p=0.003) IgG. Similarly, there were positive correlations between age and neutralization titer, though the correlations tended to be higher with ND80 compared to ND50 titer (Fig. 3). For example, the correlation coefficient of age with live-virus neutralization ND80 was rho=0.51 (p=0.001), compared to rho=0.28 (p=0.075) for ND50. No consistent significant correlations with BMI, gender or symptoms were observed (Table 3).

• Download figure
• Open in new tab

Figure 3.

Correlation analysis of plasma neutralizing potency and age of participants. A, ND50 versus age; B, ND80 versus age.